[{"indications": "Indications\u00a0invasive aspergillosis; serious infections caused by Scedosporium spp., Fusarium spp., or invasive fluconazole-resistant Candida spp. (including C. krusei)", "name": "VORICONAZOLE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.2 Antifungal drugs", "5.2.1 Triazole antifungals", "VORICONAZOLE"], "cautions": "Cautions\u00a0electrolyte disturbances, cardiomyopathy, bradycardia, symptomatic arrhythmias, history of QT interval prolongation, concomitant\r\nuse with other drugs that prolong QT interval; avoid exposure to sunlight; patients at\r\nrisk of pancreatitis; monitor renal function; interactions: Appendix 1 (antifungals, triazole)Hepatotoxicity\u00a0Hepatitis, cholestasis, and fulminant\r\nhepatic failure reported uncommonly usually in first 10 days; risk\r\nincreased in patients with haematological malignancy. Monitor liver function before treatment and during treatment", "side-effects": "Side-effects\u00a0nausea, vomiting, abdominal pain, diarrhoea, jaundice\r\n(see Hepatotoxicity above), oedema, hypotension, chest pain, respiratory\r\ndistress syndrome, sinusitis, headache, dizziness, asthenia, anxiety,\r\ndepression, confusion, agitation, hallucinations, paraesthesia, tremor,\r\ninfluenza-like symptoms, hypoglycaemia, haematuria, blood disorders\r\n(including anaemia, thrombocytopenia, leucopenia, pancytopenia), acute\r\nrenal failure, hypokalaemia, visual disturbances (including altered\r\nperception, blurred vision, and photophobia), rash, pruritus, photosensitivity,\r\nalopecia, cheilitis, injection-site reactions; less commonly dyspepsia, duodenitis, cholecystitis, pancreatitis, hepatitis (see\r\nHepatotoxicity above), constipation, arrhythmias (including QT interval\r\nprolongation), syncope, raised serum cholesterol, hypersensitivity\r\nreactions (including flushing), ataxia, nystagmus, hypoaesthesia,\r\nadrenocortical insufficiency, arthritis, blepharitis, optic neuritis,\r\nscleritis, glossitis, gingivitis, psoriasis, Stevens-Johnson syndrome; rarely pseudomembranous colitis, taste disturbances (more\r\ncommon with oral suspension), convulsions, insomnia, tinnitus, hearing\r\ndisturbances, extrapyramidal effects, hypertonia, hypothyroidism,\r\nhyperthyroidism, discoid lupus erythematosus, toxic epidermal necrolysis,\r\npseudoporphyria, retinal haemorrhage, optic atrophy; also reported\r\nsquamous cell carcinoma of skin (particularly in presence of phototoxicity\r\nor in the immunosuppressed)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/119741.htm", "doses": ["By mouth, adult and child over 12 years, body-weight\r\nover 40\u00a0kg, 400\u00a0mg every 12 hours for 2 doses then 200\u00a0mg every 12\r\nhours, increased if necessary to 300\u00a0mg every 12 hours; body-weight\r\nunder 40\u00a0kg, 200\u00a0mg every 12 hours for 2 doses then 100\u00a0mg every 12\r\nhours, increased if necessary to 150\u00a0mg every 12 hours; child 2\u201312 years, (oral suspension recommended) 200\u00a0mg\r\nevery 12 hours", "By intravenous infusion, 6\u00a0mg/kg every 12 hours\r\nfor 2 doses, then 4\u00a0mg/kg every 12 hours (reduced to 3\u00a0mg/kg every\r\n12 hours if not tolerated) for max. 6 months; child 2\u201318 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0toxicity in animal studies\u2014manufacturer\r\nadvises avoid unless potential benefit outweighs risk; effective contraception\r\nrequired during treatment"}]